The milestone is an important stage in the collaborative efforts to humanize Intellect’s lead antibody IN-N01 necessary for creating a therapeutic antibody for the treatment of Alzheimer’s disease. The antibody is intended to be used to promote clearance from the brain of the toxin that leads to Alzheimer’s disease, beta amyloid. IN-N01 is Intellect’s first drug candidate based on the technology invented by Dr. Daniel Chain, Intellect Neuroscience’s Chairman and CEO.
The MRC has approved a further £6 million of funding for a continuation of the MRCT Development Gap Fund (DGF). DGF is an innovative and successful pre-seed fund established to help exploit the cutting edge science of the MRC which could have a significant impact on the health as well as the competiveness and growth of the UK economy.
Biogen Idec and Elan Corporation, plc have announced new data on the global utilization, safety and overall…
a collaboration between teams at the MRC’s National Institute for Medical Research and MRCT’s Drug Discovery Group has produced a breakthrough in understanding how the malaria parasite triggers its release from infected red blood cells. The identification of a parasite enzyme that plays a key role in this process may provide new leads to anti-malarial drug design.
"Breakthrough by scientists in Scotland is set to ensure that the simple fruit fly plays a key…
MRCT will use its proprietary technology and advanced know-how to humanize Intellect’s beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer’s disease. The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer’s toxin, beta-amyloid, where it accumulates and causes devastating damage to victims of the disease. Humanization is an essential step in making antibodies safe for use in humans.
The collaborative agreement will cover development of a humanised antibody for the treatment of certain forms of cancer. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary CDR grafting technology to generate a humanised clinical candidate from a murine antibody discovered at Organon’s Research Center in Cambridge, MA,.
SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT will use its proprietary humanization technology to generate the humanized clinical candidate from Ginkgo Biomedical Research Institute's mouse antibody.
MRC Technologyand BioArctic Neuroscience have signed an collaborative research agreement to humanise a mouse antibody under development with BioArctic for the treatment of Alzheimer’s disease. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary humanisation technology to generate the humanised clinical candidate.